Literature DB >> 29750841

High Serum Serotonin Predicts Increased Risk for Hip Fracture and Nonvertebral Osteoporotic Fractures: The MrOS Sweden Study.

Hallgerdur Lind Kristjansdottir1, Catharina Lewerin1, Ulf H Lerner2, Ewa Waern3, Helena Johansson4, Daniel Sundh2,5, Magnus Karlsson6, Steve R Cummings7, Henrik Zetterberg8,9,10,11, Mattias Lorentzon2,3,5, Claes Ohlsson2, Dan Mellström2,3,5.   

Abstract

Because several studies have implicated serotonin as a regulator of bone mass, we here explore its potential association on fracture risk and falls, as on bone mineral density (BMD) and muscle strength, in humans. Serum levels of serotonin were analyzed in 950 men (aged 69 to 81 years), participating in the Gothenburg part of the population-based study MrOS Sweden. Men taking selective serotonin reuptake inhibitors (SSRIs) had a mean value of 31.2 μg/L compared with 159.4 μg/L in those not taking SSRIs. SSRI users were excluded from further analysis. During 10-year follow-up, 224 men exhibited fractures, including 97 nonvertebral osteoporotic fractures (57 hip fractures), and 86 vertebral fractures. Serotonin was associated with hip fracture in linear analysis (hazard ratio [HR] = 1.27, 95% confidence interval [CI] 1.03-1.58) and to all fractures in a nonlinear manner, when quintiles of serotonin was included in quadratic terms (HR = 1.12, 95% CI 1.04-1.21). Men in serotonin quintile 5 had, in multivariable analysis, a HR of 2.30 (95% CI 1.31-4.02) for hip fracture and 1.82 (95% CI 1.17-2.85) for nonvertebral fractures compared with men in quintiles 1 to 4. Men in quintile 1 had, in multivariable analysis, a HR of 1.76 (95% CI 1.03-2.99) for nonvertebral fractures compared with men in quintiles 2 to 4. No association was found with vertebral fractures. Individuals in serotonin quintile 1 had higher prevalence of falls compared with quintiles 2 to 5 (odds ratio = 1.90, 95% CI 1.26-2.87). Serotonin was positively associated with hand-grip strength (r = 0.08, p = 0.02) and inversely with hip BMD (r = -0.10, p = 0.003). To assess the association between SSRIs and falls and fractures, the total MrOS Sweden cohort was examined (n = 3014). SSRI users (n = 90) had increased prevalence of falls (16% versus 33%, p = 0.0001) and increased rate of incident fractures (28.0 versus 44.7 per 1000 person-years, p = 0.018). We present novel data showing that high levels of serotonin predict an increased risk for hip fracture and nonvertebral osteoporotic fractures.
© 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BMD; FALLS; FRACTURES; SERUM SEROTONIN; SSRI

Mesh:

Substances:

Year:  2018        PMID: 29750841     DOI: 10.1002/jbmr.3443

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  4 in total

1.  Circulating amino acids are associated with bone mineral density decline and ten-year major osteoporotic fracture risk in older community-dwelling adults.

Authors:  Yi Su; Amany Elshorbagy; Cheryl Turner; Helga Refsum; Ruth Chan; Timothy Kwok
Journal:  Bone       Date:  2019-10-14       Impact factor: 4.398

2.  Selective serotonin reuptake inhibitor use in hip fracture patients: a Danish nationwide prevalence study.

Authors:  Stine B Bruun; Irene Petersen; Nickolaj R Kristensen; Deirdre Cronin-Fenton; Alma B Pedersen
Journal:  Acta Orthop       Date:  2018-12-10       Impact factor: 3.717

3.  High platelet count is associated with low bone mineral density: The MrOS Sweden cohort.

Authors:  H L Kristjansdottir; D Mellström; P Johansson; M Karlsson; L Vandenput; M Lorentzon; H Herlitz; C Ohlsson; U H Lerner; C Lewerin
Journal:  Osteoporos Int       Date:  2020-12-11       Impact factor: 4.507

4.  Increased risk for hip fracture after death of a spouse-further support for bereavement frailty?

Authors:  C H Vala; M Lorentzon; V Sundh; H Johansson; C Lewerin; S Sten; M Karlsson; C Ohlsson; B Johansson; J A Kanis; D Mellström
Journal:  Osteoporos Int       Date:  2019-12-12       Impact factor: 4.507

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.